Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials. J of Skin 2025, 9 (6), s660. https://doi.org/10.25251/1g590e41.